HyperRAB Rabies vaccine Immune Globulin Injection is a sterile solution containing human antibodies specifically targeted against the rabies virus. It is used as part of post-exposure prophylaxis for individuals who have potentially been exposed to rabies, such as through an animal bite or scratch, and who have not previously been vaccinated against rabies. HyperRAB Rabies vaccine provides immediate, but temporary, passive immunity by supplying ready-made antibodies that help neutralize the virus until the person’s own immune system can respond to the rabies vaccine, which is administered at the same time. The medication is given by infiltrating as much of the dose as possible into and around the wound, while any remaining amount is injected into a muscle away from the site where the rabies vaccine is given. HyperRAB Rabies vaccine is used only once at the beginning of rabies post-exposure treatment and should always be combined with a rabies vaccine for full protection. Common side effects may include soreness at the injection site, mild fever, or headache, while serious allergic reactions are rare.
HyperRAB is a high-potency rabies immune globulin (Human) formulated for immediate, short-term passive immunization against the rabies virus following suspected exposure. This solution contains 300 International Units (IU) per 1 mL, designed for precise and effective administration in rabies post-exposure prophylaxis (PEP).
What It Is Used For
HyperRAB is indicated for individuals who have been exposed, or potentially exposed, to rabies virus, typically via bites, scratches, or mucosal contact from a potentially rabid animal. It is always administered in conjunction with rabies vaccine as part of the recommended rabies PEP regimen.
Important: CDC Guidelines for Use
According to the Centers for Disease Control and Prevention (CDC) guidelines:
-
Rabies Immune Globulin (RIG) must be used in conjunction with rabies vaccine for previously unvaccinated individuals.
- RIG should be infiltrated around and into the wound site as soon as possible after exposure, followed by the rabies vaccine series.
- RIG should not be administered to persons who have been previously vaccinated against rabies.
Dosage and Administration
-
Standard Dose: 20 IU/kg body weight (infiltrate as much as possible into and around the wound; any remaining should be injected intramuscularly at a site distant from vaccine administration).
-
Preparation: Each vial contains 1 mL of solution (300 IU/mL).
-
Route: Infiltration into wound(s) and/or intramuscular injection.
-
Frequency: Single administration at initiation of rabies PEP, never after day 7 of starting rabies vaccine, as it may interfere with the active immune response.
Directions
- Initiate therapy immediately after exposure.
- Calculate total volume required based on patient weight (20 IU/kg).
- Slowly infiltrate as much of the total dose as anatomically feasible around the wound(s).
- Administer the remainder intramuscularly, distant from the rabies vaccine injection site.
Mechanism of Action
HyperRAB contains concentrated antibodies (IgG) specifically active against the rabies virus. It provides immediate passive immunity by neutralizing the virus at the wound site and in tissues before the patient’s own immune response develops following vaccination.
Product Details and Features
-
NDC: 13533-0318-01
-
Manufacturer: Grifols Therapeutics
- Sterile, preservative-free, single-use vial
- High concentration (300 IU/mL) for efficient administration
- Ready-to-use liquid formulation
- Gamma globulin fraction of human plasma
- Maximum safety via donor screening, viral inactivation, and purification steps
Warnings and Precautions
-
Hypersensitivity: Contraindicated in persons with known history of anaphylactic or severe systemic reaction to human immunoglobulin preparations.
- Do NOT inject intravenously.
- Use with caution in individuals with IgA deficiency.
- Risk of transmitting infectious agents, including viruses and theoretically prions, cannot be completely eliminated due to human plasma source.
-
Do not exceed the recommended dose—excessive immunoglobulin can interfere with the efficacy of active rabies vaccination.
Side Effects
Common Adverse Reactions:
- Local reactions (pain, tenderness, erythema, bruising at injection site)
- Systemic symptoms (headache, malaise, low-grade fever, chills)
- Allergic reactions (urticaria, rash, rarely anaphylaxis)
Report any severe or unusual reactions to your healthcare provider immediately.
Storage
- Store at 2–8°C (36–46°F). Do not freeze. Protect from light.
HyperRAB 1 mL (300 IU/mL) by Grifols Therapeutics is your trusted solution for immediate immune protection following potential rabies exposure, fully compliant with CDC rabies post-exposure guidelines. Ensure proper administration for optimal results and minimized risk. Always consult your healthcare professional for individualized PEP regimens.
Order HyperRAB today for reliable, fast-acting rabies post-exposure prophylaxis!
Skip to content
